The DAF-16 transcription factor controls aging in C. elegans as part of an insulin-like signaling pathway. Identification of a target of DAF-16 has opened a new window into the aging process.
Conversely, identifying rapidly aging mutants solely with reference to lifespan is inappropriate, because the animals may die early for other reasons. In humans, some syndromes are identified as progeric because of the striking resemblance of some symptoms to normal aging. In C. elegans, a variety of phenotypes associated with aging have been known for some time, for example the accumulation of lipofuscin and protein carbonyl [6, 7] . However, these changes may be reversible [8] , which makes their relationship to aging ambiguous. Careful description of aging has expanded the range of potentially relevant aging phenotypes for study, but these phenotypes, individually or as a group, must be shown to be uniquely associated with aging for progeric mutants to be unambiguously identified. Some new aging-specific phenotypes have already been used to distinguish between true progeric mutants and mutants that shorten lifespan but do not affect aging. A recent screen turned up five genes whose RNAi phenotypes included short lifespan, but only one gene had phenotypes associated with rapid aging [6] . Phenotypic analysis by Ookuma et al. suggests that the scl-1 mutant is indeed progeric [4] .
scl-1 may be the first identified direct target of DAF-16. Some genes are functionally similar to scl-1 and daf-16 in that loss of the gene product shortens lifespan, overexpression of the gene product lengthens lifespan, or both. Some, like sir-2.1 (regulator of chromatin structure), hsf-1 (relative of heat shock transcription factor), and old-1 (receptor tyrosine kinase) are regulatory [1, 6] , while others, like mev-1 (component of electron transport chain) may function by suppressing oxidative damage [1] . Of these genes, only scl-1 has a nearby match to the optimal DAF-16 binding site. Of course, this fact does not lead to the conclusion that scl-1 is the only direct target of DAF-16. The old-1 gene, like scl-1, has daf-16-regulated expression, and like scl-1, this regulation has not been demonstrated to be direct.
What does the sequence of SCL-1 tell us about its function? SCL-1 has an SCP domain, which is found in over 300 proteins with numerous biological functions. SCL-1 subfamily genes are also highly expressed in dauer larvae [10,13]. The dauer state is a form of diapause, and is relevant to adult aging because dauers are non-aging, and many mutations that affect aging also affect regulation of the dauer state. In addition, many genes that exhibit regulated expression during aging also show expression changes in accordance with the dauer state. The scl-1 gene shows 5-fold upregulation as worms begin dauer morphogenesis and 4-to 7-fold downregulation during exit from the dauer diapause; in this respect, scl-1 is one of many genes implicated in both aging and dauer development. Many SCL-1 subfamily genes are also highly expressed in dauers. During early stages of dauer entry, scl-1 is the only SCP domain gene that shows strong upregulation. However, during dauer exit, of ten SCL-1 subfamily genes with good microarray data, six show strong downregulation. Thus, most genes in the SCL-1 subfamily show relatively high expression in dauers, but other than scl-1, most do not show strong upregulation at the beginning of dauer morphogenesis. Presumably these genes are induced later in the dauer formation process. In contrast, SCP domain genes outside the SCL-1 subfamily do not show a strong tendency to be highly expressed in dauers; two show downregulation and five show very strong upregulation in dauer exit. Thus, strong expression in dauers is mostly limited to the SCL-1 subfamily of proteins in C. elegans.
The predicted secretion of SCL-1 suggests a role in signaling, and thus SCL-1 potentially provides a tool for dissecting the role of signaling in aging. Evidence for hormonal control of aging has been found in worms, flies and mammals [2] ; but the meaning of these observations has not necessarily been clear. For example, in mice, defects in growth hormone signaling increase lifespan, but this effect may be a farremoved pleiotropy stemming from the many effects of growth hormone on development. This caveat is true to some degree in all systems.
The evidence suggesting a direct role for hormone signaling in aging is most clear in C. elegans. First, the DAF-2 insulin-like pathway functions to control lifespan with few observable pleiotropies in adults. Inactivation of the pathway in adults, even postreproductive adults, can increase lifespan, and inactivation after the completion of larval development has the same effect as inactivation throughout the lifespan [14] . This result, combined with the demonstration that the pathway acts in the nervous system to influence lifespan [15] , strongly suggests that signaling from the nervous system directly controls aging. The actual deterioration associated with aging in C. elegans is seen almost exclusively outside of the nervous system [6, 7] , thus insulin signaling within the nervous system is likely to act through an unidentified hormone to control the aging of other tissues. The conserved function of the insulin pathway in aging suggests that downstream hormonal cues will be similar, and thus suggests that the pathway will also function in adult flies and mammals to control hormones that control aging.
Other forms of signaling regulate aging in C. elegans, and these signals act in concert with the insulin pathway to control development. The Ookuma et al. paper will probably be the first drop in a deluge. With the microarray studies and systematic RNAi screens being performed in C. elegans, many genes will be identified as targets of DAF-16, as regulators of aging, or both. A couple of hours spent playing with databases allowed the identification of the SCL-1 subfamily as a group of SCP proteins with related sequence and expression, and therefore potentially related functions in aging. Understanding the mechanism by which these genes, especially genes with mysterious biochemical functions, affect aging will be a challenge to occupy aging researchers for the foreseeable future. Clearly, in the case of SCL-1 and other SCP proteins, identifying a biochemical function is a key. Perhaps in silico study of newly identified DAF-16 targets and aging genes will suggest a protein target that SCL-1 binds, or biochemical work will identify a partner. In any event, we may be starting work on the most challenging, and most interesting, part of the puzzle.
